Clinical trials
Primary Immune Thrombocytopenia (ITP) clinical trials
Below are recruiting primary immune thrombocytopenia (itp) clinical trials, each written for real people, not researchers. We’re tracking 69 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06686927RecruitingPhase 2
Steroids, IVIG, and romiplostim for severe ITP
This study tests a combination of three treatments—steroids, IVIG, and romiplostim (Nplate)—for adults with severe, newly diagnosed ITP that hasn't responded well to standard therapy. The goal is to see if this triple therapy can quickly raise platelet counts and stop bleeding.
Wuhan, HubeiAges 18–75 - NCT06721013RecruitingPhase 1/Phase 2
Study of Pirtobrutinib for immune thrombocytopenia
This trial tests a new drug called pirtobrutinib for people with immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it can help raise your platelet count and reduce bleeding risk.
Los Angeles, CaliforniaAges 18 years+ - NCT06722235RecruitingPhase 3
Mezagitamab for chronic ITP that hasn't responded to standard treatments
This study tests a new medicine called mezagitamab for adults with chronic ITP (low platelets for at least a year) who have not responded well to standard treatments. It aims to see if mezagitamab can safely raise platelet counts.
Los Angeles, CaliforniaAges 18 years+ - NCT06838962RecruitingPhase 2
Study of anti-CD38 antibody for children with chronic ITP
This trial tests a new antibody treatment (anti-CD38) for children ages 6 to 18 who have had low platelets for at least 3 months and did not improve with steroids. The goal is to see if this treatment can safely raise platelet counts.
Tianjin, Tianjin MunicipalityAges 6–18 - NCT06853444RecruitingPhase 1/Phase 2
ESG206 for adults with hard-to-treat ITP
This trial tests a new drug called ESG206 for adults with immune thrombocytopenia (ITP) whose platelet counts remain very low despite previous treatments like steroids or IVIG. The goal is to see if ESG206 can safely help raise platelet levels and reduce bleeding risk.
Jinan, ShandongAges 18 years+ - NCT06880081RecruitingPhase 1
A study of PN20 for adults with immune thrombocytopenia
This trial tests a new drug called PN20 for adults with a long-term low platelet condition called immune thrombocytopenia (ITP). It aims to see if the drug can safely raise platelet counts for people who have not gotten better with other treatments.
Guiyang, GuizhouAges 18–65 - NCT06888960RecruitingEarly Phase 1
Testing CC312 for people with autoimmune diseases
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
Tianjin, ChinaAges 18 years+ - NCT06900920RecruitingPhase 3
Study of TQB3473 tablets for adults with chronic immune thrombocytopenia
This trial tests an investigational tablet called TQB3473 against placebo for adults with primary immune thrombocytopenia (ITP) that has lasted at least a year and hasn't responded well to standard treatments. The goal is to see if the drug can safely increase platelet counts and reduce bleeding risk.
Hefei, AnhuiAges 18–75 - NCT06919341Recruiting
Spanish immune thrombocytopenia registry
This study collects data from people with immune thrombocytopenia (a condition where the immune system destroys platelets, causing low blood counts). It aims to better understand and track the disease over time.
A Coruña, A CoruñaAges 2 months+ - NCT06929299RecruitingPhase 1/Phase 2
Testing STSA-1301 for immune thrombocytopenia (ITP)
This trial tests a new drug called STSA-1301 for people with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The study has two parts: one for healthy volunteers to check safety, and one for ITP patients to see if the drug can raise platelet counts and reduce bleeding risk.
Bengbu, AnhuiAges 18–75 - NCT06973356Recruiting
CAR-T therapy for severe, hard-to-treat ITP
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (CD19 and BCMA) on immune cells. It is for adults with severe ITP that has not improved with other treatments. The goal is to reset the immune system to stop attacking platelets.
Changsha, HunanAges 18 years+ - NCT06992128RecruitingPhase 2
Romiplostim plus steroids for newly diagnosed ITP
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07007962RecruitingPhase 3
Oral pill for immune thrombocytopenia after first treatment fails
This trial tests an oral medicine called rilzabrutinib for adults with immune thrombocytopenia (ITP) whose first treatment stopped working or who need steroids long-term. The goal is to see if it helps raise platelet counts and reduce bleeding risk.
Clovis, CaliforniaAges 18 years+ - NCT07063199RecruitingPhase 2
Anti-CD38 antibody for older adults with hard-to-treat ITP
This trial tests an investigational antibody (anti-CD38) for older adults with ITP that hasn't improved with standard treatments. The goal is to see if this antibody can safely raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 60 years+ - NCT07065968RecruitingPhase 2
Teriflunomide and steroids for new immune thrombocytopenia
This trial tests if adding teriflunomide to high-dose dexamethasone helps adults newly diagnosed with immune thrombocytopenia (ITP) who have low platelets or bleeding. It aims to find a safer, more effective way to raise platelet counts.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07095127RecruitingPhase 2
Testing NVG-2089 for immune thrombocytopenia
This trial tests an investigational drug called NVG-2089 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if it safely raises platelet counts and improves bleeding symptoms.
Greenville, North CarolinaAges 18–80 - NCT07133659RecruitingPhase 4
New starting dose of avatrombopag for immune thrombocytopenia
This study tests a modified starting dose of avatrombopag, a medication that helps raise platelet counts, in adults with immune thrombocytopenia (ITP) who have not responded well to first-line steroid treatments. The goal is to see if this new dosing is effective and safe.
BaghdadAges 18 years+ - NCT07206758RecruitingPhase 1
Study of SHR-2173 for immune thrombocytopenia (ITP)
This study tests a new medication called SHR-2173 for people with immune thrombocytopenia (ITP) whose platelet count is low and who have already tried steroids without success. The goal is to see if this drug can help raise platelet counts and reduce bleeding risk.
Wuhan, HubeiAges 18 years+ - NCT07206823Recruiting
Romiplostim N01 plus rituximab for ITP that didn't respond to oral TPO-RA
This trial tests a new combination of two medicines—romiplostim N01 (a shot to raise platelets) and rituximab (an infusion that calms the immune system)—for people with primary immune thrombocytopenia (ITP) who have not had enough improvement from oral TPO-RA pills like hetrombopag or eltrombopag. It aims to see if this combination works better and is safe.
Suzhou, JiangsuAges 14 years+ - NCT07233213RecruitingPhase 3
IVIG for chronic low platelet condition
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
Ankara, AltındağAges 18–65 - NCT07234019RecruitingPhase 2
Rituximab plus anti-CD38 antibody for ITP
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07294365RecruitingPhase 2
Study of DZD8586 for adults with chronic ITP
This study tests an investigational drug called DZD8586 for people with long-term ITP (low platelets) that hasn't improved with standard treatments. The goal is to see if it can safely raise platelet counts and reduce bleeding risk.
Jinan, ShandongAges 18 years+ - NCT07297563RecruitingPhase 2
Anti-CD38 antibody vs rituximab for hard-to-treat ITP
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07362199RecruitingPhase 2
New combo treatment for chronic ITP
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new Primary Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary immune thrombocytopenia (itp)?
- Yes. Clin2 currently lists 69 recruiting primary immune thrombocytopenia (itp) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary immune thrombocytopenia (itp) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary immune thrombocytopenia (itp) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.